

Applicants have amended their claims so that they are all directed to 5, 6, or 7 membered rings.

The 1,2 thiazine type compounds of Claim 19 have been rejected as not being patentably distinct from the claims of the parent application, Serial No. 07/775,313, now U.S. Patent No. 5,240,923. Applicants respectfully traverse the rejection. The racemic form of the first compound set forth in Claim 19 of the present application is claimed in the '923 parent, none of the other compounds of Claim 19 are claimed in the '923 patent. Applicants respectfully request reconsideration.

Claims 19, 23, 27, and 32, have been rejected under 35 USC § 101 as the statute provides for a patent. Applicants respectfully traverse the rejection. As explained previously, none of the compounds of Claim 19, from which 23, 27 and 32 depend, are claimed in U.S. Patent No. 5,240,923. Applicants respectfully request reconsideration.

In view of the above restriction and discussion, Applicants have amended their claims to eliminate non-fused compounds. In view thereof, Applicants submit their claims are in condition for allowance and notice thereof is respectfully requested.

Respectfully submitted,

ALCON LABORATORIES, INC.

Oct 19, 1993
Date

Sally S. Yeager
Sally S. Yeager
Reg. No. 32,757

Address for Correspondence:
Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, TX 76134
(817) 551-4031
Docket No. 1158C